Six organizations ask HHS Secretary Azar to take title of 5 patents on Exondys 51, as remedy to failure by inventors to disclose NIH funding

FOR IMMEDIATE RELEASE April 5, 2018 kim.treanor@keionline.org (202)-332-2670 Six organizations are asking Department of Health and Human Services Secretary Alex Azar to take actions to lower the price of eteplirsen, a drug sold under the brand name Exondys 51, to… Continue Reading

KEI requests that federal government use compulsory licenses on Kaléo held patents for devices used to administer opioid overdose reversal drug

KEI has submitted a request to Mr. James Carroll, Acting Director of the Office of National Drug Control Policy, and to Ms. Kellyanne Conway, Counselor to the President and appointed “opioid czar,” asking that the federal government use its authority… Continue Reading

James Griffin, Dana-Farber Cancer Institute and Novartis failure to disclose NIH funding for patents on leukemia drug midostaurin (Trade name Rydapt)

On March 21, 2018, KEI asked the NIH to investigate the failure of James Griffin, the Dana-Farber Cancer Institute and Novartis to disclose millions of dollars in NIH grants related to two patents for the leukemia drug midostaurin, marketed by… Continue Reading

30+ Civil Society Orgs to USTR: Stop Threatening to Block Colombia’s OECD Accession over Pharma/Biotech Lobby Interests

FOR IMMEDIATE RELEASE March 20, 2018 kim.treanor@keionline.org (202)-332-2670 A broad international coalition of over 30 human rights organizations, including some across the United States and Latin America, have come together to ensure that providing access to health care doesn’t come… Continue Reading

Six University of Pennsylvania and Daniel J. Rader patents on Juxtapid (lomitapide) failed to discuss multiple NIH grants

On March 29, 2018, KEI asked the NIH to investigate the failure of the University of Pennsylvania and Daniel J. Rader to report NIH funding relating to 6 patents in the FDA Orange Book for the drug Juxtapid (INN lomitapide).… Continue Reading